Tag Archives: NCI contract

  • 0

3 KIYATEC Posters @AACR 2016

Tags : 

Three KIYATEC abstracts accepted for poster presentations during 2016 AACR Conference in New Orleans

KIYATEC, a private company prioritizing accurate ex vivo prediction of patients’ response to drug treatment, received acceptance of three posters for presentations during the upcoming AACR conference.

GREENVILLE, SC, March 21, 2016– KIYATEC Inc. is pleased to announce that three abstracts have been accepted by the committee at the American Association for Cancer Research (www.aacr.org).  KIYATEC scientific and business development staff will be in attendance at the conference.  In addition to the poster presentations, also KIYATEC will be exhibiting at Booth 1050.  Stop by to learn more about our 10+ years of 3D cell culture experience and the latest 3D co-culture model development projects focused on immuno-oncology applications.

  •  Abstract #611: A Complex 3D Model of Glioblastoma for Patient-Specific Drug Response Profiling  | Sunday Apr 17, 2016 1:00 PM – 5:00 PM | Location: Section 28 / Poster 12
  • Abstract #2531: Marker free isolation and expansion of cancer stem cells from small cell lung cancer | Monday, Apr 18, 2016, 1:00 PM – 5:00 PMLocation: Section 34 / Poster 20
  • Abstract # 5119: Complex, 3D tissues for modeling the immune response in cancer and predicting the activity of immunotherapies | Wednesday Apr 20, 2016 8:00 AM – 12:00 PM | Location: Section 31 / Poster 5

Ex Vivo 3D Cancer Models

  • 0

$2M NCI Contract To Advance Predictive Cancer Diagnostics

Tags : 

National Cancer Institute Awards KIYATEC Nearly $2M to Advance Predictive Cancer Diagnostics

Contract Funds 3D Breast Cancer, 3D Brain Cancer Micro-Tumor Development

GREENVILLE, SC | September 18, 2014 – KIYATEC announced today that it has been awarded a $1.975 million, Small Business Innovation Research (SBIR) Phase II Contract from the National Cancer Institute (NCI), one of the 27 institutes and centers that comprise the National Institutes of Health (NIH). Over the course of the two year award, KIYATEC will expand its 3D breast cancer model to address two issues at the forefront of cancer therapy strategies: 1) cancer’s interaction with the patient’s immune system (immuno-oncology) and 2) cancer’s interaction with the patient’s blood supply (angiogenesis). The award will also allow KIYATEC to broaden its technology platform beyond its current use in primary ovarian cancer and breast cancer testing and into glioblastoma multiforme (GBM), a type of brain cancer with a five year survival rate that is less than 10 percent. The funded contract has the potential to radically change the future of cancer patient care.

Predictive 3D Cancer Diagnostics